GLPwatch
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916 · Completed
Last updated 2026-05-28This trial tests whether the medication orforglipron helps people with obesity or overweight maintain weight loss they have already achieved.
Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 376 people
Who can join Ages 18+ · all sexes
Timeline Started 2024-09 · est. completion 2025-11
Where 29 sites · Puerto Rico, United States
What this study is testing ClinicalTrials.gov NCT06584916 ↗
Description as written by the study sponsor.
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.
Treatments tested
- Orforglipron Drug
Administered orally
- Placebo Drug
Administered orally
| Main thing measured | Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Obesity, Overweight |
| GLP-1 drugs | orforglipron |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06584916 ↗